Brian Hubbard, Anji Pharmacetuticals CEO

Look­ing to rewrite the rules of drug li­cens­ing, start­up An­ji is on the hunt for 'dy­nam­ic eq­ui­ty' joint ven­tures

Li­cens­ing is one of the most com­mon ways big drug­mak­ers lever­age biotech in­no­va­tion to dri­ve gains across their pipelines — and the struc­ture of those deals is pret­ty well es­tab­lished. But one biotech with home bases in Chi­na and the US thinks it may have a bet­ter way.

On Tues­day, Cam­bridge-based biotech An­ji Phar­ma closed a $70 mil­lion Se­ries B with two late-stage mol­e­cules in the fold and a mis­sion to rewrite the rules of drug li­cens­ing through what it calls “dy­nam­ic eq­ui­ty” deals and a joint ven­ture-heavy game plan. The round was fund­ed in whole by Chi­nese hedge fund CR Cap­i­tal.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.


Alexandria Real Estate Equities

San Diego, CA, USA